bioAffinity Technologies, Inc. - SIC # 8071 - MEDICAL LABORATORIES

Ticker Exchange SIC # Website Latest Ticker
BIAF Nasdaq 8071 bioaffinitytech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for bioAffinity Technologies, Inc.

BIAF Stock Slips Post Q1 Earnings Despite Strength in CyPath Lung - May 14th, 2026 8:27 am
bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026 - May 12th, 2026 7:15 am
bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung - May 8th, 2026 6:30 am
bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment - Apr 28th, 2026 7:16 am
bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally? - Apr 16th, 2026 7:55 am
New Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy - Apr 14th, 2026 6:00 am
bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual "Advances in Early Lung Cancer Detection" Symposium April 16 - Apr 7th, 2026 6:00 am
bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026 - Apr 1st, 2026 6:00 am
bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice - Mar 25th, 2026 6:00 am
BC-Most Active Stocks - Mar 23rd, 2026 8:30 am
New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures - Mar 17th, 2026 5:45 am
bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung - Mar 13th, 2026 6:00 am
bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic - Mar 10th, 2026 5:47 am
BIAF vs. GH: Which Cancer Detection Stock Is the Better Buy Now? - Mar 5th, 2026 9:51 am
bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients - Mar 3rd, 2026 6:30 am
bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test - Feb 25th, 2026 6:30 am
New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer - Feb 19th, 2026 9:00 am
Clinical Utility of bioAffinity Technologies’ CyPath® Lung Test Demonstrated in Real-World Case Study - Feb 17th, 2026 6:00 am
bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board - Feb 9th, 2026 6:00 am
bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation - Jan 7th, 2026 6:00 am